Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(1):1-4
DOI: 10.5428/pcar20190101
Safety of GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus
1. LI Wenwen(Department of Endocrinology,Changhai Hospital,Navy Military Medical University, Shanghai 200433,China liwenwen19960130@126.com)
2. WANG Qijin(Department of Endocrinology,Changhai Hospital,Navy Military Medical University, Shanghai 200433,China wangqi jin8668601@163.com)
ABSTRACT  Glucagon-like peptide-1(GLP-1) receptor agonists and sodium-glucose cotransporter 2(SGLT2) inhibitors,which are the new drugs for treatment of patients with type 2 diabetes,have been widely applied in clinic.This article summarizes the safety of these two new drugs,the effects on hypoglycemia and diabetic ketoacidosis,and possible effects on various systems,such as the cardiovascular system,the digestive system,the genitourinary system,the skeletal system and the thyroid gland.Applying the drugs under safety instructions in clinic can bring out the advantages to the maximum in treating type 2 diabetes.
Welcome to PCAR! You are the number 389 reader of this article!
Please cite this article as:
LI Wenwen,WANG Qijin,. Safety of GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 1-4.
References:
1. Diabetes Branch of Chinese Medical Association.Chinese guidelines for type 2 diabetes prevention and treatment (2017 ed)[J].Chin J Diabetes Mellitus,2018,10(1):4-67.In Chinese.
2. Levin P A.Practical combination therapy based on pathophysiology of type 2 diabetes[J].Diabetes Metab Syndr Obes Targets Ther,2016,9:355-369.
3. Wilding J P H,Rajeev S P,DeFronzo R A.Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm[J].Diabetes Care,2016,39(2):S154-S164.
4. Miller M E,Williamson J D,Gerstein H C,et al.Effects of randomization to intensive glucose control on adverse events,cardiovascular disease,and mortality in older versus younger adults in the ACCORD Trial[J].Diabetes Care,2014,37(3): 634-643.
5. Seaquist E R,Miller M E,Bonds D E,et al.The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study[J].Diabetes Care,2012,35(2):409-414.
6. Consoli A,Formoso G,Baldassarre M P A,et al.A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment[J].Expert Opin Drug Saf,2018,DOI:10.1080/14740338.2018.1428305.
7. Ogawa W,Sakaguchi K.Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors:possible mechanism and contributing factors[J].J Diabetes Investig,2016,7(2):135-138.
8. Yokono M,Takasu T,Hayashizaki Y,et al.SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats[J].Eur J Pharmacol,2014,727(1):66-74.
9. Goldenberg R M,Berard L D,Cheng A Y Y,et al.SGLT2 inhibitor associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis[J].Clin Ther,2016,38(12):2654-2664.
10. Marso S P,Bain S C,Consoli A,et al.Semaglutide and cardiovascular outcomes in paitients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844.
11. Lovshin J A.Glucagon-like peptide receptor agonists: a class update for treating type 2 diabetes[J].Can J Diabetes,2017,41(5):524-535.
12. Goud A,Zhong Jixin,Peters M,et al.GLP-1 agonists and blood pressure: a review of the evidence[J].Curr Hypertens Rep,2016,18(2):16.
13. Neal B,Perkovic V,Mahaffey K W,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.
14. Scheen A J.GLP-1 receptor agonists and heart failure in diabetes[J].Diabetes Metab,2017,43:2S13-2S19.
15. Wanner C,Inzucchi S E,Lachin J M,et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(4):323-334.
16. Marso S P,Daniels G H,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.
17. Sikirica M V,Martin A A,Wood R,et al.Reasons for discontinuation of GLP-1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes[J].Diabetes Metab Syndr Obes,2017,10:403-412.
18. YANG Lin,HE Zhiyu,TANG Xulei,et al.Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis[J].Eur J Gastroenterol Hepatol,2013,25:225-231.
19. Elashoff M,Matveyenko A V,Gier B,et al.Pancreatitis,pancreatic,and thyroid cancer with glucagon-like peptide-1-based therapies[J].Gastroenterology,2011,141:150-156.
20. Neumiller J J,Alicic R Z,Tuttle K R.Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease[J].J Am Soc Nephrol,2017,28(8):2263-2274.
21. ZOU Honghong,ZHOU Baoqin,XU Gaosi.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease[J].Cardiovasc Diabetol,2017,16:65.
22. McHugh K R,DeVore A D,Mentz R J,et al.The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes[J].Clin Cardiol,2018,41:1259-1267.
23. Nauck M A.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J].Drug Des Devel Ther,2014,8:1335-1380.
24. LIU Jiali,LI Ling,LI Sheyu,et al.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis[J].Sci Rep,2017,7:1-11.
25. Wilding J P,Woo V,Soler N G,et al.Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin[J].Dtsch Med W ochenschr,2013,138(Suppl 1):S27-S38.
26. LUO Guojing,LIU Hong,LU Hongyun.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?[J].Br J Clin Pharmacol,2016,81(1):78-88.
27. Kohler S,Salsali A,Hantel S,et al.Safety and tolerability of empagliflozin in patients with type 2 diabetes[J].Clin Ther,2016,38:1299-1313.
28. Ljunggren ,Bolinder J,Johansson L,et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab,2012,14:990-999.
29. Bjerre Knudsen L,Madsen L W,Andersen S,et al.Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation[J].Endocrinology,2010,151:1473-1486.
30. Hegedüs L,Moses A C,Zdravkovic M,et al.GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog,liraglutide[J].J Clin Endocrinol Metab,2011,96(3):853-860.
31. Mathieu P,Boulanger M C,Despres J P.Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk[J].Rev Endocr Metab Disord,2014,15(4):289-298.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口